Safety and tolerability of the glutamate antagonist cgs 19755 (selfotel) in patients with acute ischemic stroke: Results of a phase iia randomized trial

James Grotta, Wayne Clark, Bruce Coull, L. Creed Pettigrew, Bruce Mackay, Larry B. Goldstein, Irene Meissner, Deborah Murphy, Linda Larue

Research output: Contribution to journalArticle

169 Scopus citations

Abstract

Background and Purpose CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke.

Original languageEnglish (US)
Pages (from-to)602-605
Number of pages4
JournalStroke
Volume26
Issue number4
DOIs
StatePublished - Apr 1995

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this